Eli Lilly’s stock plunges as investors eye obesity-drug competition
Eli Lilly & Co.’s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying ...
Hosted on MSN9mon
Amgen’s obesity drug puts stock on pace for best day since 2009 as analysts predict big gains to come
Fueled by upbeat management comments on an experimental obesity treatment, Amgen’s stock was on pace early Friday for its best day since 2009 — and analysts see more gains ahead as the company ...